English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

The in vivo effects of pegylated recombinant human megakaryocyte growth and development factor (PEG‐rHuMGDF), a truncated molecule of recombinant human thrombopoietin modified with polyethylene glycol, were investigated in normal Balb/c mice. PEG‐rHuMGDF was more potent in producing platelets and the dose‐response curve was steeper compared with the case of the nonpegylated form of this molecule. Five consecutive injections with PEG‐rHuMGDF caused a dose‐dependent increase in peripheral platelet counts with a peak on day 8. There was a dose‐dependent rise in platelet counts on day 8 at daily doses from 0.333 to 30 μg/kg. Intermediate doses of PEG‐rHuMGDF (1.111 to 10 μg/kg/day) caused a significant decrease in mean platelet volume, and conversely, higher doses of PEG‐rHuMGDF (30 to 270 μg/kg/day) induced a dose‐dependent increase in mean platelet volume. There was a dose‐dependent decrease in hemoglobin concentration with a minimum on day 8 but no significant reduction in reticulocyte counts following PEG‐rHuMGDF administration. White blood cell counts were unchanged by PEG‐rHuMGDF treatment. Marrow megakaryocyte size enlarged to 1.5‐fold and the number of marrow megakaryocytes increased to sixfold by consecutive administration of PEG‐rHuMGDF at 30 μg/kg/day. A twofold increase in the number of marrow megakaryocytic progenitor cells (colony‐forming units‐megakaryocyte) was also observed. Marrow erythroid progenitor (colony forming units‐erythroid) counts decreased by splenic colony‐forming units‐erythroid, marrow and splenic erythro/myeloid progenitor cell counts, and splenic granulocyte/macrophage progenitor cell counts increased with PEG‐rHuMGDF treatment. Marrow and splenic erythroid burst‐forming cells were unchanged. These results indicate that PEG‐rHuMGDF, a truncated molecule of thrombopoietin, is a potent stimulator for megakaryopoiesis and thrombopoiesis, and also affects the development of other hematopoietic cells in normal mice.

In Vivo Effects of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor on Hematopoiesis in Normal Mice